Cognoa preps FDA filing for digital autism diagnostic
pharmaphorum
SEPTEMBER 24, 2020
The FDA has awarded a breakthrough device designation to the app, which means it should have a swift review with a higher level of input from the US regulator. In the US, it is estimated that one in five children are living with a diagnosable behavioural health disorder, however, only 21% of children who are diagnosed receive treatment.
134 
Let's personalize your content